| Literature DB >> 32764462 |
Tomohisa Takagi1,2, Ryotaro Hayashi3, Yuji Nakai4, Shinji Okada5, Rumiko Miyashita3, Mayumi Yamada6, Yoichi Mihara7, Katsura Mizushima1, Mayuko Morita8, Kazuhiko Uchiyama1, Yuji Naito1, Yoshito Itoh1.
Abstract
Metabolic syndrome, whose main diagnostic component is obesity, is a risk factor for lifestyle-related diseases, type 2 diabetes, and cardiovascular disease. Diet is known to affect the prevalence of metabolic syndrome. However, the effect of diet on metabolic syndrome in Japanese subjects has not been thoroughly explored. In the present study, we investigated the effect of carotenoid-rich vegetables, particularly lycopene- and lutein-rich vegetables, on the metabolic syndrome in obese Japanese men. We conducted an 8-week long randomized, double-blinded, controlled clinical trial in which, 28 middle-aged (40 ≤ age < 65) Japanese men with high body mass index (BMI ≥ 25) were randomized into four dietary groups: high lycopene + high lutein (HLyHLu), high lycopene + low lutein (HLyLLu), low lycopene + high lutein (LLyHLu), and low lycopene + low lutein (LLyLLu). Our results showed that daily beverage-intake increased the plasma levels of carotenoids without adverse effects, and the visceral fat level was significantly decreased in all the groups. The waist circumference was significantly decreased only in the HLyLLu group, whereas the CoQ10 oxidation rate was decreased in all the groups. The gene expression profiles of whole blood samples before and after ingestion differed only in the LLyLLu group, indicating the effect of carotenoids on gene expression profile. In conclusion, our results suggest that dietary uptake of carotenoid-rich vegetables increases their concentration in blood and reduces the intra-abdominal visceral fat.Entities:
Keywords: carotenoids; lutein; lycopene; metabolic syndrome; visceral adiposity
Mesh:
Substances:
Year: 2020 PMID: 32764462 PMCID: PMC7468729 DOI: 10.3390/nu12082342
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Enrollment and follow-up of obese men who participated in the present randomized, double-blind study.
Figure 2Representative pictures of TCH-722 carrots (a) and TCL-499 kale (b).
The contents of carotenoids and dietary fibers contained in the test beverages produced from vegetables.
| (A) High Lycopene + High Lutein (HLyHLu Group) | (B) High Lycopene + Low Lutein (HLyLLu Group) | (C) Low Lycopene + High Lutein (LLyHLu Group) | (D) Low Lycopene + Low Lutein (LLyLLu Group) | |
|---|---|---|---|---|
| α-carotene | 1.88 | 1.8 | 0.12 | 0.12 |
| β-carotene | 13.44 | 10.92 | 6.92 | 3.72 |
| Lycopen | 7.56 | 8.6 | 0 | 0 |
| Lutein | 1.96 | 0.12 | 2.48 | 0.16 |
| Fiber | 6.4 | 4.4 | 6.8 | 4 |
The assessment of plasma carotenoids levels at baseline and after 8 weeks of intervention.
| (A) High Lycopene + High Lutein | (B) High Lycopene + Low Lutein | (C) Low Lycopene + High Lutein | (D) Low Lycopene + Low Lutein | |||||
|---|---|---|---|---|---|---|---|---|
| 0 wks | 8 wks | 0 wks | 8 wks | 0 wks | 8 wks | 0 wks | 8 wks | |
| α-carotene (μg/dL) | 5.0 ± 4.93 | 14.1 ± 5.42 ** | 5.2 ± 5.44 | 14.1 ± 5.51 * | 7.1 ± 8.17 | 8.1 ± 7.28 | 5.12 ± 5.11 | 4.02 ± 3.19 |
| β-carotene (μg/dL) | 15.6 ± 14.34 | 52.5 ± 38.37 ** | 10.7 ± 7.99 | 30.3 ± 13.53 ** | 21.0 ± 14.50 | 52.0 ± 32.52 ** | 16.4 ± 6.90 | 26.5 ± 11.02 * |
| Lycopen (μg/dL) | 45.0 ± 28.90 | 74.1 ± 27.28 ** | 35.0 ± 26.42 | 54.7 ± 28.40 | 38.4 ± 28.05 | 47.6 ± 46.21 | 35.5 ± 28.56 | 39.52 ± 42.57 |
| Lutein (μg/dL) | 39.6 ± 11.10 | 66.5 ± 22.64 ** | 33.7 ± 10.34 | 44.1 ± 19.32 | 37.9 ± 7.82 | 69.3 ± 27.34 | 41.3 ± 28.05 | 38.1 ± 26.19 |
All values represent the means (± standard deviation, SD). * p < 0.05, ** p < 0.01 vs. values at baseline.
The physical assessment at baseline and after 8 weeks of intervention.
| (A) High Lycopene + High Lutein | (B) High Lycopene + Low Lutein | (C) Low Lycopene + High Lutein | (D) Low Lycopene + Low Lutein | |||||
|---|---|---|---|---|---|---|---|---|
| 0 wks | 8 wks | 0 wks | 8 wks | 0 wks | 8 wks | 0 wks | 8 wks | |
| Body Weight (kg) | 81.3 ± 10.48 | 81.5 ± 10.16 | 80.6 ± 4.08 | 80.4 ± 3.98 | 86.5 ± 13.49 | 86.7 ± 13.70 | 95.8 ± 18.63 | 96.6 ± 18.54 |
| Waist Circumference (cm) | 96.9 ± 8.23 | 96.7 ± 9.41 | 98.0 ± 5.00 | 95.8 ± 4.66 * | 97.4 ± 7.32 | 97.6 ± 9.08 | 104.4 ± 14.94 | 105.4 ± 16.67 |
| Body Mass Index (BMI) | 28.1 ± 3.09 | 28.2 ± 3.07 | 27.9 ± 1.78 | 27.8 ± 1.72 | 28.2 ± 3.05 | 28.2 ± 3.16 | 31.4 ± 5.42 | 31.6 ± 5.45 |
| Visceral Fat Level | 15.2 ± 1.89 | 14.2 ± 2.25 ** | 14.8 ± 1.52 | 14.0 ± 1.27 ** | 14.6 ± 2.59 | 13.8 ± 2.91 * | 17.0 ± 2.72 | 16.4 ± 2.75 ** |
All values represent the means (± standard deviation, SD). * p < 0.05, ** p < 0.01 vs. values at baseline.
The assessment of fasting glucose, HDL/LDL/total cholesterol, and triglycerides at baseline and after 8 weeks of intervention.
| (A) High Lycopene + High Lutein | (B) High Lycopene + Low Lutein | (C) Low Lycopene + High Lutein | (D) Low Lycopene + Low Lutein | |||||
|---|---|---|---|---|---|---|---|---|
| 0 wks | 8 wks | 0 wks | 8 wks | 0 wks | 8 wks | 0 wks | 8 wks | |
| Fasting glucose (mg/dL) | 94.0 ± 11.42 | 89.3 ± 7.70 | 92.0 ± 11.40 | 91.0 ± 9.38 | 93.4 ± 6.00 | 92.7 ± 5.65 | 88.2 ± 9.36 | 94.8 ± 9.23 |
| HDL cholesterol (mg/dL) | 46.1 ± 6.41 | 45.7 ± 8.62 | 59.4 ± 30.29 | 53.8 ± 22.59 | 46.9 ± 5.84 | 48.4 ± 6.37 | 41.8 ± 6.83 | 39.4 ± 9.15 |
| LDL cholesterol (mg/dL) | 146.1 ± 30.47 | 153.9 ± 30.32 | 121.0 ± 39.56 | 130.4 ± 28.05 | 136.0 ± 34.73 | 149.7 ± 38.25 * | 158.0 ± 20.16 | 153.2 ± 46.80 |
| Total cholesterol (mg/dL) | 219.3 ± 31.98 | 225.1 ± 27.22 | 210.2 ± 13.61 | 211.4 ± 11.06 | 205.6 ± 38.41 | 213.9 ± 42.53 | 246.6 ± 35.24 | 230.6 ± 42.0 |
| Triglycerides (mg/dL) | 165.1 ± 66.87 | 203.1 ± 71.30 | 149.2 ± 112.92 | 180.4 ± 112.53 | 111.1 ± 42.53 | 135.1 ± 30.46 | 212.8 ± 105.55 | 323.8 ± 261.61 |
All values represent the means (± standard deviation, SD). * p < 0.05 vs. values at baseline.
The assessment of oxidative markers and proinflammatory cytokines (IL-6 and TNF-α) at baseline and after 8 weeks of intervention.
| (A) High Lycopene + High Lutein | (B) High Lycopene + Low Lutein | (C) Low Lycopene + High Lutein | (D) Low Lycopene + Low Lutein | |||||
|---|---|---|---|---|---|---|---|---|
| 0 wks | 8 wks | 0 wks | 8 wks | 0 wks | 8 wks | 0 wks | 8 wks | |
| sLOX-1 (ng/L) | 525.9 ±185.61 | 606.9 ± 272.91 | 525.9 ± 212.21 | 439.3 ± 143.26 | 465.6 ± 245.41 | 391.3 ± 160.98 | 643.3 ± 263.59 | 684.7 ± 283.55 |
| %CoQ10 (%) | 10.7 ± 1.47 | 8.0 ± 1.73 * | 9.4 ± 1.38 | 7.2 ± 2.09 * | 10.6 ± 1.17 | 7.5 ± 1.34 ** | 13.1 ± 4.96 | 8.9 ± 2.70 * |
| IL-6 (pg/mL) | 1.3 ± 1.1 | 1.1 ±0.62 | 1.2 ± 1.09 | 1.3 ± 1.32 | 1.1 ± 1.35 | 0.9 ± 1.09 | 1.0 ± 0.71 | 1.2 ± 0.6 |
| TNF-α (pg/mL) | 1.4 ± 0.47 | 1.3 ± 0.47 | 1.2 ± 0.12 | 1.0 ± 0.20 | 1.4 ± 0.38 | 1.1 ± 0.23 | 1.5 ± 0.48 | 1.3 ± 0.43 |
All values represent the means (± standard deviation, SD). * p < 0.05, ** p < 0.01 vs. values at baseline.
Figure 3Comparison of the gene expression profiles in the subjects’ blood before (0 W) and after (8 W) the test. (A) Principal component analysis was performed using DNA microarray data from individual blood. (A) before the test (0 W); (B) after the test (8 W). The proportion of variance is indicated in parenthesis after each principal component. The ellipses represent 90% confidence intervals of the group. (B) The area ratio of 8W to 0W probability ellipses for each group.